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BACKGROUND: The C677T functional variant in the methylenetetrahydrofolate reductase (MTHFR) gene leads to
reduced enzymatic activity and elevated blood homocysteine levels. Hyperhomocysteinemia has been linked with
higher rates of cardiovascular diseases, cognitive decline, and late-life depression.
METHODS: Three-dimensional magnetic resonance imaging data were analyzed from 738 individuals (aged 75.5 6
6.8 years; 438 men, 300 women), including 173 patients with Alzheimer’s disease, 359 subjects with mild cognitive
impairment, and 206 healthy older adults, scanned as part of the Alzheimer’s Disease Neuroimaging Initiative.
RESULTS: We found that this variant associates with localized brain atrophy, after controlling for age, sex, and
dementia status, in brain regions implicated in both intellectual and emotional functioning, notably the medial
orbitofrontal cortices. The medial orbitofrontal cortex is involved in the cognitive modulation of emotional processes,
and localized atrophy in this region was previously linked with both cognitive impairment and depressive symptoms.
Here, we report that increased plasma homocysteine level mediates the association between MTHFR genotype and
lower medial orbitofrontal volumes and that these volumes mediate the association between cognitive decline and
depressed mood in this elderly cohort. We additionally show that vitamin B12 deﬁciency interacts with the C677T
variant in the etiology of hyperhomocysteinemia.
CONCLUSIONS: This study sheds light on important relationships between vascular risk factors, age-related
cognitive decline, and late-life depression, and it represents a signiﬁcant advance in our understanding of clinically
relevant associations relating to MTHFR genotype.
Keywords: Age-related cognitive decline, Brain atrophy, Homocysteine, Late-life depression, MRI, MTHFRISShttp://dx.doi.org/10.1016/j.bpsc.2016.09.005Hyperhomocysteinemia, a metabolic anomaly involving ele-
vated blood levels of the amino acid homocysteine, is
associated with higher rates of numerous age-related disor-
ders, such as cardiovascular diseases (1,2) including vascular
dementia (3,4); cognitive decline (5–9); and depressed mood
(10–12). Elevated plasma homocysteine levels may stem from
the use of certain therapeutic drugs, from elevated alcohol
ingestion, from intestinal malabsorption, or from impaired
metabolism due to genetic alterations in metabolic enzymes,
including methylenetetrahydrofolate reductase (MTHFR), most
commonly when combined with insufﬁcient dietary intake of B
vitamins. Notably, homocysteine is recycled to methionine
using vitamin B12 as a cofactor, and MTHFR, the rate-limiting
enzyme in the methyl cycle, catalyzes the conversion of
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a
cosubstrate for homocysteine remethylation by methionine
synthase. These relationships are illustrated in Figure 1.
We recently reported that older adults with higher homo-
cysteine levels had more pronounced regional brain atrophy
(13) and thinner cortical gray matter (14) on magnetic& 2016 Society of Biological Psychiatry. Pub
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SEE COMMENTAresonance imaging (MRI). We also found that the C677T
variant in MTHFR was associated with smaller regional
brain volumes in two independent elderly cohorts with mild
cognitive impairment (MCI) (15). Increased susceptibility for
cardiovascular diseases (16), which are strongly linked to both
cognitive decline and depressive symptoms in old age (17), are
also associated with the C677T variant.
Here, we ﬁrst determined whether our previously reported
associations between the T “risk” allele and more pronounced
brain atrophy extended beyond individuals with MCI to both
patients with dementia and healthy older adults. We further
sought to model some of the mechanisms underlying relation-
ships between brain integrity, clinical outcomes, and the
genetic and environmental modulators of homocysteine
metabolism. To this end, we ﬁrst examined whether the effects
of this MTHFR polymorphism on medial orbitofrontal volumes
were mediated by its impact on plasma homocysteine levels.
We also determined whether vitamin B12 deﬁciency inﬂuenced
the strength of the relationship between this variant and
homocysteine levels. We then found that lower cognitivelished by Elsevier Inc. This is an open access article under the
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1
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Figure 1. Simpliﬁed illustration of the one-carbon cycle. MTHFR, methy-
lenetetrahydrofolate reductase; SAH, S-adenosyl-L-homocysteine; SAM,
S-adenosyl-L-methionine.
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signiﬁcant predictors of depressed mood and tested the
hypothesis that compromised integrity in this brain region
involved in the cognitive control of emotion may partially
explain the relationship between cognitive impairment and
depressive symptoms.
METHODS AND MATERIALS
Subjects
We analyzed a large sample of elderly individuals from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI). The study
was conducted according to the Good Clinical Practice
guidelines, the Declaration of Helsinki, and U.S. 21 CFR Part
50 (Protection of Human Subjects) and Part 56 (Institutional
Review Boards). Written informed consent was obtained
from all participants before protocol-speciﬁc procedures
were performed. All ADNI data are publicly available
(http://adni.loni.usc.edu). To avoid the known effects of2 Biological Psychiatry: Cognitive Neuroscience and Neuroimaging ]]]population stratiﬁcation on genetic analysis (18), we included
only non-Hispanic Caucasian subjects identiﬁed by self-report
and conﬁrmed by multidimensional scaling analysis (19). The
ADNI cohort included multiple diagnostic groups: patients with
Alzheimer’s disease (AD), subjects with MCI, and healthy
elderly (cognitively normal) participants. All subjects were
administered the Mini–Mental State Examination (MMSE) (20)
and the 15-item version of the Geriatric Depression Scale
(GDS-15) (21). Our ﬁnal analysis comprised 738 individuals
(average age 6 SD 5 75.53 6 6.78 years; 438 men, 300
women), including 173 AD, 359 MCI, and 206 healthy older
adults. All participants received premortem clinical diagnoses,
as described in detail in ADNI’s General Procedures Manual
(http://adni.loni.usc.edu/wp-content/uploads/2010/09/ADNI_
GeneralProceduresManual.pdf). Table 1 illustrates demo-
graphic, cognitive, and mood data for all participants, stratiﬁed
by genotype and substratiﬁed by diagnostic groups.Genotyping and Allele Frequency
The ADNI sample was genotyped using the Illumina 610-Quad
BeadChip (Illumina, Inc., San Diego, CA). The only polymor-
phism examined in this study was the C677T functional variant
in the MTHFR gene, at the rs1801133 locus. Allele frequency
was computed from genotype frequency. Distributions of allele
frequencies by diagnostic groups were evaluated by χ2 tests
with a .05 signiﬁcance level, using 3 3 2 and 2 3 2
contingency tables in SPSS, version 23.0 (IBM Corp.,
Armonk, NY).Neuroimaging
Whole-Brain Analyses: Tensor-Based Morphometry.
The C677T polymorphism was analyzed for association with
regional brain volumes in ADNI participants, as detailed below.
Subjects were scanned using a standardized MRI protocol
developed for this cohort (22,23). Brieﬂy, high-resolution
structural brain magnetic resonance images were acquired at
58 sites across North America, using 1.5T MRI scanners.
A sagittal three-dimensional magnetization-prepared rapid
gradient-echo sequence was used, optimized for consistency
across sites (23) (repetition time/echo time 5 2400/1000 ms;
ﬂip angle 5 81; ﬁeld of view 5 24 cm; ﬁnal reconstructed voxel
resolution 5 0.9375 3 0.9375 3 1.2 mm3). Image corrections
were applied using a processing pipeline at the Mayo Clinic,
consisting of 1) a procedure termed GradWarp to correct
geometric distortion due to gradient nonlinearity (24), 2) a
“B1-correction” to adjust for image intensity inhomogeneity
due to B1 nonuniformity using calibration scans (23), 3)
“N3” bias ﬁeld correction for reducing residual intensity
inhomogeneity (25), and 4) geometrical scaling, according to
a phantom scan acquired for each subject (23), to adjust for
scanner- and session-speciﬁc calibration errors. To adjust for
global differences in brain positioning and scale, all subjects’
scans were linearly registered to the stereotaxic space deﬁned
by the International Consortium for Brain Mapping template
(ICBM-53) (26) using a nine-parameter transformation (three
translations, three rotations, three scales) (27). We used
standard trilinear interpolation and resampled the resulting
aligned scans to have 1-mm isotropic voxels.2016; ]:]]]–]]] www.sobp.org/BPCNNI
Table 1. Demographic Data by Diagnostic and C677T Genotype Groups (N 5 738)
CC CT TT Total Group Comparisons
CON n 84 (37 F) 96 (45 F) 26 (12 F) 206 (94 F) p 5 .929
Age, years 75.95 6 4.75 [76] 75.98 6 5.00 [75] 77.42 6 5.59 [77] 76.15 6 4.98 [76] p 5 .380
MMSE 29.25 6 0.94 [30] 29.08 6 0.99 [29] 29.08 6 0.85 [29] 29.15 6 0.95 [29] p 5 .464
GDS-15 1.06 6 1.25 [1] 0.68 6 1.14 [0] 0.92 6 0.89 [1] 0.86 6 1.17 [0] p 5 .089
MCI n 149 (57 F) 157 (54 F) 53 (17 F) 359 (128 F) p 5 .656
Age, years 75.27 6 6.88 [76] 75.02 6 7.50 [76] 75.15 6 7.45 [74] 75.14 6 7.22 [76] p 5 .957
MMSE 26.96 6 1.74 [27] 27.06 6 1.83 [27] 27.55 6 1.75 [28] 27.09 6 1.78 [27] p 5 .115
GDS-15 1.58 6 1.29 [1] 1.59 6 1.42 [1] 1.28 6 1.28 [1] 1.54 6 1.35 [1] p 5 .330
AD n 81 (40 F) 67 (25 F) 25 (13 F) 173 (78 F) p 5 .256
Age, years 75.04 6 7.69 [76] 75.91 6 7.30 [77] 76.48 6 8.34 [77] 75.58 6 7.61 [77] p 5 .644
MMSE 23.33 6 1.88 [23] 23.45 6 2.22 [24] 23.24 6 1.81 [23] 23.36 6 2.00 [23] p 5 .892
GDS-15 1.64 6 1.42 [1] 1.58 6 1.35 [1] 1.84 6 1.55 [1] 1.65 6 1.40 [1] p 5 .737
Total n 314 (134 F) 320 (124 F) 104 (42 F) 738 (300 F) p 5 .602
Age, years 75.39 6 6.61 [76] 75.50 6 6.80 [76] 76.04 6 7.26 [77] 75.53 6 6.78 [76] p 5 .697
MMSE 26.64 6 2.70 [27] 26.91 6 2.63 [27] 26.89 6 2.67 [28] 26.79 6 2.66 [27] p 5 .399
GDS-15 1.50 6 1.33 [1] 1.31 6 1.39 [1] 1.33 6 1.30 [1] 1.38 6 1.35 [1] p 5 .382
n indicates sample sizes, followed by the number of women in parentheses. Average age, MMSE, and GDS-15 scores are followed by SDs.
Median values are indicated in brackets. p values for Pearson χ2 tests (for sex) or one-way analyses of variance (for age, MMSE, and GDS-15
scores) are reported in the last column.
AD, Alzheimer’s disease; CON, healthy controls; F, female; GDS-15, 15-item version of the Geriatric Depression Scale; MCI, mild cognitive
impairment; MMSE, Mini–Mental State Examination.
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serves as an unbiased average template image for automated
image registration and serves to reduce statistical bias. The
minimal deformation target was created from the magnetic
resonance images of 40 randomly selected healthy elderly
subjects, as detailed elsewhere (28,29). To quantify three-
dimensional patterns of volumetric tissue variations, all indi-
vidual T1-weighted images were nonlinearly aligned to the
template with an inverse-consistent three-dimensional elastic
warping technique using a mutual information cost function
(30). Consequently, for each subject, a separate Jacobian
matrix ﬁeld was derived from the gradients of the deformation
ﬁeld that aligned that individual brain to the minimal deforma-
tion target. The determinant of the local Jacobian matrix was
derived from the forward deformation ﬁeld to characterize
local volume differences. Color-coded Jacobian determinants
were used to illustrate regions of volume expansion, that
is, those with det J(r) . 1, or contraction, that is, det J(r) , 1
(31–34) relative to the group template. Because all images
were registered to the same study-speciﬁc template, these
Jacobian maps shared common anatomical coordinates,
deﬁned by the normal template. Individual Jacobian maps
were retained for further statistical analyses.
To model effects of the C677T functional variant in MTHFR
on local brain volumes, we used univariate linear regression to
associate the number of minor T alleles (0, 1, or 2) with the
Jacobian values (describing the amount of brain tissue deﬁcit
or excess relative to the standard template) at each voxel in the
brain, after controlling for age, sex, and diagnosis. To minimize
type I errors, we used a searchlight method for false discovery
rate correction (35), which controls the false discovery rate in
all reported statistical maps. We implemented this method to
correct the maps of statistical associations between the image
phenotype (morphometry) and genotype at the rs1801133Biological Psychiatry: Cognitive Neuroscienclocus (number of T alleles). All maps shown were thresholded
at the appropriate corrected p value, after performing search-
light false discovery rate (q 5 0.05), to show only regions of
signiﬁcance that passed the multiple comparisons correction.Region of Interest Analyses: Medial Orbitofrontal
Volumes. Five MRI core analysis laboratories have provided
feature extraction and numeric summaries from the high-quality
ADNI MRI data, which are publicly available in the ADNI data
archive (http://adni.loni.usc.edu). One of these core analysis
laboratories, the Center for Imaging of Neurodegenerative
Diseases at the University of California, San Francisco (co-
investigator: Norbert Schuff), has provided volumetric segmen-
tation using the FreeSurfer image analyses suite, which is
documented and freely available for download online (http://
surfer.nmr.mgh.harvard.edu/). Version 4.3 is used for ADNI’s
cross-sectional data. The input for ADNI FreeSurfer is a T1-
weighted image in Neuroimaging Informatics Technology Initia-
tive (NiFTI) format, which has been preprocessed (gradient
warping, scaling, B1 correction, and N3 inhomogeneity correc-
tion) by the Mayo Clinic preprocessing stream as described
above.
Brieﬂy, FreeSurfer processing includes motion correction,
removal of nonbrain tissue using a hybrid watershed/surface
deformation procedure (36), automated Talairach transforma-
tion, segmentation of the subcortical white matter and deep
gray matter (37,38), intensity normalization (25), tessellation of
the gray matter/white matter boundary, automated topology
correction (39,40), and surface deformation following intensity
gradients to optimally place the gray/white and gray/cerebro-
spinal ﬂuid borders at the location where the greatest shift in
intensity deﬁnes the transition to the other tissue class (41–43),
followed by rigorous quality control procedures that allow fore and Neuroimaging ]]] 2016; ]:]]]–]]] www.sobp.org/BPCNNI 3
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quality, registration issues, or processing errors. We down-
loaded the numeric summaries for “medial orbital frontal”
volumes and retained the data pertaining to subjects with
frontal segmentations that satisﬁed all quality control require-
ments. We obtained the volumes of the medial orbitofrontal
cortices (in cubic millimeters) for 640 of our participants.
Blood-Based Markers
In the ADNI public database, plasma homocysteine levels
were available for 732 of our participants, 634 of whom also
had usable medial orbitofrontal volumes. The database also
contained plasma vitamin B12 concentrations for 680 of our
subjects (including 675 with available homocysteine levels and
587 with both homocysteine and medial orbitofrontal volume
data). Homocysteine and vitamin B12 levels (in picograms per
milliliter) were extracted from blood samples collected via
standard venipuncture protocols. Vitamin B12 deﬁciency was
deﬁned as plasma levels , 250 pg/mL.
Statistical Analyses
To ensure consistency, we used an additive model of minor
T-allele effects—the number of T alleles carried by each
participant was coded as 0, 1, or 2—in all analyses aimed at
testing the association between the C677T variant and another
variable. However, because medial orbitofrontal volumes
seemed to be affected in a recessive manner, we additionally
ran every regression model using a recessive model of minor
allele effects (i.e., comparing C-allele carriers with T homo-
zygotes). These analyses produced similar results, which are
presented in Supplemental Tables S2–S4.
We used general linear models to examine the predictors of
medial orbitofrontal volumes, plasma homocysteine concen-
trations, and GDS-15 scores. Shapiro-Wilk tests showed that
medial orbitofrontal volumes were normally distributed
(p 5 .601), but homocysteine levels (p , .001) and GDS-15
scores (p , .001) were not. We therefore used standardized
scores in all regression models including plasma homocys-
teine levels or mood scores as the dependent variable. Age
and sex were included as covariates in all analyses. We also
controlled for diagnosis, except when MMSE score was used
as a factor in the model, because MMSE scores are one of the
major diagnostic criteria for dementia, as described in ADNI’s
General Procedures Manual (http://adni.loni.usc.edu/wp-con
tent/uploads/2010/09/ADNI_GeneralProceduresManual.pdf).
These statistical analyses were conducted in SPSS,
version 23.0.Table 2. Genotype and Allele Frequency by Diagnostic Groups
CON
Total N 5 738 206
Genotype Frequency CC 84 (41%)
CT 96 (46%)
TT 26 (13%)
Allele Frequency C 264 (64%)
T 148 (36%)
AD, Alzheimer’s disease; CON, healthy controls; MCI, mild cognitive im
4 Biological Psychiatry: Cognitive Neuroscience and Neuroimaging ]]]Simple mediation analyses were conducted using Andrew
Hayes’s PROCESS Procedure (version 2.15) for SPSS (http://
www.processmacro.org/download.html). We obtained path
coefﬁcients (a, b, c, and c0) representing the linear regression
coefﬁcients for each path in the mediation model. We stand-
ardized all variables to facilitate the interpretation of path
coefﬁcients, now bounded by 21 and 1 across all measures.
The a-path represents the association between the predictor
and mediator variables. The b-path denotes the relationship
between the mediator and outcome variables, while also
controlling for the predictor variable. The c0-path (also called
“direct effect”) and the c-path (also known as “total effect”)
represent the associations between the predictor and out-
come variables including and excluding the mediator variable,
respectively. If the difference between c and c0 is statistically
signiﬁcant, there is a signiﬁcant mediation effect. It was
previously shown that a 3 b 5 c 2 c0; therefore, we tested
the signiﬁcance of a 3 b (also known as “indirect effect”)
using bootstrapped conﬁdence intervals (CIs) (44). Bootstrap-
ping creates thousands of simulated datasets using resam-
pling with replacement and runs the analysis once in each
simulated sample (45). Of the generated statistics, 95% fall
between two values, and if that CI for a 3 b does not include 0,
a signiﬁcant (p , .05) mediation has occurred. Percent
mediation [PM] is a measure of effect size interpreted as the
percent of the total effect (c) accounted for by the indirect
effect (a 3 b); that is, PM 5 (a 3 b)/c (44).RESULTS
Consistent with the prevailing view that the MTHFR C677T
polymorphism may not be a risk factor for AD, but appears to
be associated with various types of age-related disorders (46),
the distributions of genotype (p 5 .592) and allele frequency
(p 5 .667) for rs1801133 did not signiﬁcantly differ across the
three diagnostic groups in the ADNI cohort (Table 2). None-
theless, this functional variant in MTHFR predicted differences
in regional brain volumes in our large elderly sample after
controlling for age, sex, and diagnosis. As depicted in
Figure 2, smaller volumes in the frontal (including the bilateral
cingulate gyri, middle frontal gyri, lateral and medial orbito-
frontal cortices), parietal (notably the inferior parietal lobule),
and temporal lobes (especially the superior temporal gyrus), as
well as in the thalamus, were statistically related to carrying
the minor T allele at the rs1801133 locus. Strong genotype
group differences were also observed in periventricular
regions. Each copy of the “risk” allele was associated with a
2% to 4% reduction in local brain volumes (Figure 2).(N 5 738)
MCI AD Pearson χ2 Test
359 173
149 (41%) 81 (47%) p 5 .592
157 (44%) 67 (39%)
53 (15%) 25 (14%)
455 (63%) 229 (66%) p 5 .667
263 (37%) 117 (34%)
pairment.
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Figure 2. Effects of the C677T variant on regional brain volumes (N 5
738). Negative beta values (warm colors) show regions in which each risk
T allele was associated with a 2% to 4% volume deﬁcit, as shown on the
color bar. Tests for associations are adjusted for age, sex, and diagnosis;
maps are corrected for multiple comparisons with the searchlight false
discovery rate method at q 5 0.05. Images are in radiological convention
(left side of the brain shown on the right).
Figure 3. Mediation of the association between genotype and medial
orbitofrontal volumes by plasma homocysteine levels (n 5 634). Path
coefﬁcients for simple mediation analysis using the PROCESS Procedure
for SPSS. The a-path represents the association between genotype and
plasma homocysteine levels. The b-path denotes the relationship between
plasma homocysteine levels and medial orbitofrontal volumes while also
controlling for genotype. The c0-path and c-path represent the associations
between genotype and medial orbitofrontal volumes with and without
plasma homocysteine levels included as a mediator, respectively.
*p , .05, ***p , .001.
Figure 4. Partial mediation of the association between performance on
the Mini-Mental State Examination (MMSE) and scores on the 15-item
version of the Geriatric Depression Scale (GDS-15) by medial orbitofrontal
volumes (n 5 640). Path coefﬁcients for simple mediation analysis using the
PROCESS Procedure for SPSS. The a-path represents the association
between MMSE scores and medial orbitofrontal volumes. The b-path
denotes the relationship between medial orbitofrontal volumes and GDS
scores while also controlling for MMSE performance. The c0-path and the c-
path represent the associations between MMSE and GDS scores with and
without medial orbital cortical volumes included as a mediator, respectively.
*p , .05, **p , .01, ***p , .001.
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MTHFR genotype in our whole-brain analyses, the medial
orbitofrontal cortex was particularly noteworthy because of its
involvement, not just in mood states and intellectual function-
ing, but speciﬁcally in the cognitive modulation of emotional
processes. This brain area therefore was selected as the
region of interest in our investigations of the relationships
between brain integrity, clinical outcomes, and homocysteine
metabolism. Our region of interest analyses, which used
FreeSurfer volumes in a subset of the same elderly sample
(Supplemental Table S1), conﬁrmed that the C677T variant
was associated with reduced medial orbitofrontal volumes
(p 5 .033, F ratio 5 3.428) after controlling for age, sex, and
diagnosis (Supplemental Table S2). As expected, the C677T
variant was also associated with signiﬁcant elevations in
plasma homocysteine levels (p , .001, F ratio 5 10.375) after
controlling for age, sex, and dementia status (Supplemental
Table S2). Mediation analyses further revealed a signiﬁcant
indirect effect of the number of T alleles on medial orbitofrontal
volumes through plasma homocysteine levels, a 3 b 5
20.015 (95% CI, 20.039 to 20.003). The mediator accounted
for about one-quarter of the total effect, PM 5 0.253 (Figure 3).
We then tested the hypothesis that the relationship
between genotype and plasma homocysteine concentrations
may differ between individuals with inadequate circulatory
levels of vitamin B12 (i.e., who are deﬁcient in a major cofactor
used by methionine synthase to remethylate homocysteine
into methionine) and nondeﬁcient subjects by introducing
vitamin B12 deﬁciency status as a covariate in addition to
age, sex, and diagnosis in the regression models. The C677T
variant showed even stronger associations with elevations in
plasma homocysteine levels (p , .001, F ratio 5 12.143),
vitamin B12 deﬁciency was an independent predictor of
homocysteine concentrations (p 5 .021, F ratio 5 5.348),
and the genotype-by-deﬁciency status interaction term wasBiological Psychiatry: Cognitive Neurosciencsigniﬁcant (p 5 .011, F ratio 5 4.529), supporting our
hypothesis (Supplemental Table S3). Within-group analyses
conﬁrmed that in vitamin B12–deﬁcient individuals, carrying the
allele conferring reduced enzymatic activity was more strongly
associated with increased plasma homocysteine concentra-
tions (p 5 .008, F ratio 5 5.122) than in nondeﬁcient subjects
(p 5 .055, F ratio 5 2.911) after controlling for age, sex, and
dementia status (Supplemental Table S3).
We subsequently examined predictors of GDS-15 scores
across the entire sample. We found no signiﬁcant main effects
of the C677T variant (p 5 .256, F ratio 5 1.368), homocysteine
levels (p 5 .823, F ratio 5 0.050), or vitamin B12 deﬁciency
status (p 5 .961, F ratio 5 0.002) on mood scores. However,
cognitive decline, assessed with the MMSE (p , .001,e and Neuroimaging ]]] 2016; ]:]]]–]]] www.sobp.org/BPCNNI 5
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F ratio 5 7.840) were associated with greater depressive
symptoms (i.e., higher GDS-15 scores) after controlling for
age and sex (Supplemental Table S4). Further analyses
revealed a signiﬁcant partial mediation of MMSE-GDS asso-
ciations by medial orbitofrontal volumes, a 3 b 5 20.012
(95% CI, 20.027 to 20.003). The mediator accounted for
about 8% of the total effect, PM 5 0.075 (Figure 4). These
results are summarized in Supplemental Figure S1.DISCUSSION
The C677T functional variant in MTHFR is a risk factor for
hyperhomocysteinemia and has been associated with higher
rates of various age-related disorders (46). This study expands
on our earlier report of a link between the C677T variant and
regional brain atrophy in two independent elderly cohorts with
MCI (15) by providing evidence for these associations across
the spectrum of normal cognitive aging, MCI, and AD. For the
ﬁrst time in this report, we address the mechanisms through
which genetic variation in MTHFR alters brain integrity and
affects mood-cognition associations in the elderly. These
novel ﬁndings bring together prior work reporting that both
the C677T variant (15) and plasma homocysteine levels (13)
are signiﬁcant predictors of reduced regional brain volumes in
older adults. These results also suggest the importance of
adequate vitamin B12 intake, especially in carriers of the
thermolabile variant, consistent with a prior report highlighting
the signiﬁcance of this vitamin in relation to homocysteine-
induced regional brain atrophy (47).
Whole-brain tensor-based morphometry analyses revealed
associations between the C677T variant and reduced volumes
in several brain regions involved in intellectual functioning
(e.g., the middle frontal gyrus and inferior parietal lobule) and
in the regulation of emotional and cognitive aspects of goal-
directed behavior (e.g., the superior temporal gyrus, cingulate
gyrus, and orbitofrontal cortex). In particular, the medial
orbitofrontal cortex is a functionally complex structure with
extensive projections to and from primary sensory cortices,
different prefrontal regions and other association areas, limbic
structures, and the medial temporal lobe. It is implicated in
high-level aspects of cognition and mediates important
aspects of emotional behavior. Notably, converging evidence
from multiple lines of study suggests its involvement in the
cognitive modulation of the affective and reward value of
stimuli and emotion-related states (48).
Medial orbitofrontal atrophy occurs early in the course of
dementia (49,50), and structural abnormalities in this region
have been associated with depressive symptoms in both
middle-aged (51) and geriatric (52–54) subjects. In fact, the
largest ever and most recent worldwide meta-analysis of
cortical thickness reductions in depressed patients relative
to controls reported the largest effect sizes in medial orbito-
frontal cortices (55). Cognitive decline in the elderly is fre-
quently accompanied by depressed mood (56,57), and
neurodegeneration appears to play an important role in the
pathogenesis of depression associated with cognitive con-
cerns (58). Here, we examined predictors of mood scores and
found that the only two variables signiﬁcantly associated with
depressive symptoms were medial orbitofrontal atrophy and6 Biological Psychiatry: Cognitive Neuroscience and Neuroimaging ]]]cognitive impairment. We also uncovered a signiﬁcant medi-
ation of these mood-cognition associations by medial orbito-
frontal volumes, thereby integrating ﬁndings from multiple prior
studies.
Our tensor-based morphometry analyses also showed
signiﬁcant associations between the C677T variant and
reduced volumes in periventricular regions. A decrease in the
size of periventricular structures allows the ventricles to
expand; thus, this ﬁnding appears consistent with prior reports
of an association between plasma homocysteine level and
ventricular enlargement in older adults (59,60). However, this
result should be interpreted with caution. Movement artifacts
are sometimes more evident at tissue interfaces where
changes in signal intensity are most pronounced, such as
along the brain–cerebrospinal ﬂuid border, and head motion
during MRI acquisition can also tend to reduce gray matter
volume and thickness estimates (61). Moreover, participant
motion is increased in elderly and clinical populations (62), and
most image processing methods combined with the exclusion
of low-quality scans based on visual inspection are not always
sufﬁcient to fully account for motion as a confounding variable
(61). Therefore, despite the rigorous motion correction and
quality control procedures implemented in this study, we
cannot exclude the possibility that the periventricular volume
differences we observed may be due in part to greater head
motion.
Carriers of the T allele have higher plasma homocysteine
concentrations, as evidenced by multiple genome-wide asso-
ciation studies (63–67). Homocysteine is prothrombotic and
proatherogenic, resulting in damage to vessel walls. It is also
toxic to neurons by multiple mechanisms, including inﬂamma-
tion and pro-oxidation, direct DNA damage, and glutamate
excitotoxicity (68). Elevated homocysteine levels have been
associated with brain atrophy in the elderly, which may be due
to the cerebrovascular as well as the direct neurotoxic effects
of this amino acid. Notably, we showed that higher plasma
homocysteine levels predicted regional brain volume deﬁcits in
older adults (13), and the present study suggests that our
previously reported associations between the C677T variant
and more pronounced brain atrophy in MCI (15) also apply to
patients with dementia and healthy older adults. Here, we
additionally show that the effect of this polymorphism on
medial orbitofrontal volumes is mediated by increased plasma
homocysteine levels, which further elucidates a possible
causal pathway between MTHFR genotype and brain tissue
loss in the elderly.
Our results also suggest that vitamin B12 deﬁciency inter-
acts with the C677T variant in the etiology of hyperhomocys-
teinemia and associated disorders. Although it may be
possible to offset the pathogenic effects of certain variants
by dietary supplementation, our ﬁndings imply that the same
interventions may be ineffective in individuals who do not carry
these variants. This provides a potential explanation for the
discrepancies reported in studies evaluating the efﬁcacy
of supplementation with B vitamins (69). The metabolism of
homocysteine is complex; thus, stratifying participants by
genetic and physiological risk factors for hyperhomocysteine-
mia—or a combined risk index based on genetic, imaging, and
peripheral blood markers—may allow for more sensitive and
focused future clinical trials of degenerative brain diseases2016; ]:]]]–]]] www.sobp.org/BPCNNI
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of B vitamins can have detrimental effects in some individuals
(70), this report also highlights the importance of personalized
medicine in determining appropriate levels of B vitamin intake
and underscores the need for novel approaches to reducing
plasma homocysteine concentrations [e.g., by enhancing the
conversion of this amino acid to cysteine in the liver or by
supporting its urinary excretion (71)].
Since the Alzheimer’s Disease Neuroimaging Initiative was
established in 2004, more than 500 studies of the ADNI
dataset have been published and have resulted in numerous
major accomplishments (72). Notably, following the identiﬁca-
tion of novel genetic risk factors for age-related disorders,
many studies have focused on associations between these
risk variants and brain measures. These include our prior
reports of the effects of Alzheimer’s risk variants in APOE and
CLU on ventricular expansion rate (73) and obesity-related
polymorphism in FTO on regional brain atrophy (74). An
important insight from this line of study was the understanding
that genetic risk factors affect the trajectory of brain aging
even in cognitively normal individuals. Another area of focus in
research using ADNI data has been the elucidation of relation-
ships between blood metabolite levels and various imaging,
genetic, and clinical correlates. Examples include our prior
studies of associations between plasma leptin levels and brain
volumes (75) and between serum cholesterol levels, a
cholesterol-related gene, and white matter microstructure
(76). This line of study has led to a better understanding of
the link between different biomarkers associated with aging
and neurodegenerative disorders.
The present report goes one step further and proposes a
mechanistic model of the relationships among three clusters
of information: homocysteine metabolism (MTHFR genotype,
vitamin B12 deﬁciency, plasma homocysteine concentrations),
regional brain volumes, and clinical symptoms (MMSE and
GDS-15 scores). We found that the association between the
C677T variant and reduced volumes of medial orbitofrontal
cortices was mediated by increased plasma homocysteine
levels, and that the link between cognitive impairment and
depressive symptoms was partially mediated by decreased
medial orbitofrontal volumes, suggesting that this functional
variant may affect the relationship between cognitive decline
and depressed mood in older adults, perhaps through its
effect on regional atrophy in brain regions involved in the
cognitive modulation of emotional processes.
Future studies are needed to provide a validation of these
models in different elderly cohorts. It is also important for
future investigations to address how this genetic variant
interacts with other polymorphisms [especially variants that
also confer a predisposition to hyperhomocysteinemia, such
as those in the ZNF366 and PTPRD genes (64)] and with
environmental factors (including vitamin deﬁciencies, alcohol
consumption, and therapeutic drug use) to affect the trajectory
of brain aging, and indirectly, intellectual and emotional
functioning in older adults. Nonetheless, by modeling some
of the mechanisms through which the C677T variant affects
regional brain volumes and how these changes relate to
cognitive impairment and depressive symptoms across the
spectrum of healthy aging, MCI, and AD, this study represents
an important advance in our understanding of clinicallyBiological Psychiatry: Cognitive Neurosciencrelevant associations relating to this widely studied polymor-
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